Abstract:Objective To analyze the efficacy and safety of different treatments in advanced lung adenocarcinoma patients with v-raf murine sarcoma viral oncogene homolog B1(BRAF) BRAF V600E mutation, human epidermal growth factor receptor 2 (HER2) mutation, rearranged during transfection (RET) fusion gene and EGFR exon 20 insertion (EGFR 20-ins)mutations in order to provide references for clinical guidance. Methods A retrospective cohort study was performed on 14 patients with BRAF V600E mutation, 22 patients with HER2 mutation, 20 patients with RET fusion gene and 15 patients with EGFR 20-ins mutation who were admitted to our hospital between October 2019 and December 2021. The patients from different mutation groups were divided into chemotherapy±bevacizumab subgroup, chemotherapy+immune checkpoint inhibitors(ICIs) subgroup, and selective targeted drug subgroup. The efficacy and adverse events were compared in each mutation group. Results In the first-line treatment of the patients with BRAF V600E mutation, the median progression-free survival (mPFS) was longer in the dabrafenib-trametinib subgroup than the chemotherapy±bevacizumab subgroup and chemotherapy+ICIs subgroup (15.8 vs 6.3 and 4.7 months, P=0.426 5), but there were significant differences. In the first-line treatment of HER2-positive patients, the mPFS in the chemotherapy+immune subgroup was statistically better than the chemotherapy±bevacizumab subgroup and the HER2 inhibitor subgroup (8.7 vs 5.2 and 2.9 months, P=0.013 5). In the first-line treatment of the patients with RET fusion gene, the mPFS in the RET inhibitor subgroup was longer than that of the chemotherapy±bevacizumab subgroup and that of the chemotherapy+ICIs subgroup, without statistical significances (17.5 vs 7.8 and 6.7 months, P=0.092 3). Conclusion Targeted therapeutic drugs may be more effective in advanced lung adenocarcinoma patients with BRAF V600E mutation and RET fusion gene than those at first-line, while chemotherapy combined with immunotherapy may be more effective in the patients with HER2-positive at first line.

Clinical characteristics and survival analysis of rare mutations in locally advanced or metastatic lung adenocarcinoma